A Phase I, Open-label Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Subjects

20190317

The primary objectives of this study are to evaluate the effect of AMG 510 on the pharmacokinetics (PK) of metformin in healthy participants and to evaluate the effect of metformin on the PK of AMG 510 in healthy participants.

2019-11-13

2019-11-25

2019-11-25

Completed

Early phase I

13

Inclusion Criteria: 1. Healthy male participants or female participants, between 18 and 60 years of age (inclusive), at the time of Screening. 2. Body mass index, between 18 and 30 kg/m\^2 (inclusive), at the time of Screening. 3. Females of nonchildbearing potential. Exclusion Criteria: 1. Inability to swallow oral medication or history of malabsorption syndrome. 2. History of hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) and in consultation with the Sponsor. 3. Poor peripheral venous access. 4. History or evidence, at Screening or Check in, of clinically significant disorder, condition, or disease not otherwise excluded that, in the opinion of the Investigator (or designee), would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 13, 'type': 'ACTUAL'}}

2023-01-11